Moderna's stock decline after RFK Jr's appointment makes an "attractive entry point": Piper Sandler
Moderna’s (NASDAQ:MRNA) steep fall on Friday after President-elect Donald Trump selected vaccine critic Robert F. Kennedy Jr.